読み込み中
NASDAQHealthcareBiotechnology
最新データ
$259.86
−$3.69 · -1.40%
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
前日終値
$259.86
−$3.69 · -1.40%
日中の時刻はETです。市場データは遅延する場合があります。
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
日中レンジ
現在 $259.86
52週レンジ
現在 $259.86
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
30
割高
センチメント
75
強気
リスク
60
やや高いリスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
日中レンジ
現在 $259.86
52週レンジ
現在 $259.86
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 855.3万 USD | 244.7万 USD | — | — |
| 売上原価 | 14万 USD | 1.52億 USD | 8676.6万 USD | 1.54億 USD | — |
| 粗利益 | −14万 USD | −1.44億 USD | −8431.9万 USD | −1.54億 USD | — |
| 研究開発 | 2.67億 USD | 1.52億 USD | 8676.6万 USD | 1.55億 USD | 1.2億 USD |
| 販売・一般管理 | 5908.3万 USD | 5630.5万 USD | 4205.4万 USD | 5954.6万 USD | 4707.5万 USD |
| 営業費用 | 3.26億 USD | 5630.5万 USD | 4205.4万 USD | 6054.6万 USD | 1.67億 USD |
| 受取利息 | 2293万 USD | 1734.6万 USD | — | — | — |
| 減価償却費と償却費 | 14万 USD | 35.8万 USD | 43.2万 USD | 41.9万 USD | 18.2万 USD |
| 営業利益 | −3.26億 USD | −2億 USD | −1.26億 USD | −2.15億 USD | −1.67億 USD |
| 純利益 | −3.03億 USD | −1.83億 USD | −1.23億 USD | −2.14億 USD | −1.67億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$603.83
上昇余地（132.37%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2023年11月29日 | 1:15 | — | — |
発効済み 2023年11月29日
1:15
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.11億0.01%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.25億0.12%1853億 USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM1.74億0.22%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap Value ETFVBR1.34億0.20%682億 USD0.05%$234.43+0.22%
State Street SPDR S&P Biotech ETFXBI1.14億1.16%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF1.07億0.11%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO6119.18万0.44%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB5363.08万0.51%108.2億 USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
